Masimo Goes Public, Building On Recent Pulse Oximetry Market Share Gains
This article was originally published in The Gray Sheet
Executive Summary
Pulse oximetry device maker Masimo's successful initial public stock offering Aug. 8 reflects in part the company's ability to capitalize on a doubling of its market share over the past two years
You may also be interested in...
Covidien Faces Challenge Of Accelerating Growth After Spin-Off From Tyco
Newly independent medical technology firm Covidien plans select acquisitions and divestitures as well as increased licensing activity to help accelerate growth following its June 29 spin-off from parent company Tyco International
GPOs May Spurn Anti-Competitive Contracts After Masimo v. Tyco – MDMA
Masimo believes its $420 mil. legal victory over Tyco will spur large manufacturers and GPOs to gradually alter their business practices, resulting in long-term cost savings for hospitals
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.